Abstract 4130
Background
Information on outcomes after cessation of anti-PD-1 mAb for CR are scarce outside KN-001 & 006 trials. We investigated these outcomes in the French pembro EAP, where pts were less selected than in registration trials.
Methods
A multicenter ambispective cohort of advanced melanoma pts initiating pembro between May 2014-Sept 2015 (CCTIRS, #15.640) was searched for pts who achieved CR. Overall and progression-free survivals with Log rank tests were used to compare curves.
Results
687 pts (159 with brain metastases) were included from 41 centers, which covered 75% of French pembro EAP. 79 pts (13%) achieved CR, among whom 68 (10%) stopped pembro for CR. Compared with the remaining 619 pts surveyed, these 68 pts had lower baseline serum LDH levels (54.5% vs 73.8%, respectively, were normal, p = 0.016), lower ECOG PS (ECOG 0 for 298 (52.6%) and 54 (80.6%), respectively, p = 0.001), and fewer metastatic sites (p = 0.003). Of note, 10% of these 68 pts had >3 metastatic sites, 10% had brain metastases, 53% had 2010 AJCC stage M1c melanoma, and 67% had received previous treatment for advanced melanoma (mainly ipilimumab). Frequency of BRAFV600, NRAS, and c-kit mutation status was not different between pts who did or did not achieve CR. Median duration on pembro in these 68 pts was 21.2 m (range: 2.5-48.4, SD 10.0). Pembro was used alone to achieve CR in 79% of pts, while 4% received concurrent radiotherapy alone, 10% concurrent surgery alone, and 6% both treatments. At the cut-off date (13/09/2018), after a median follow-up since pembro initiation of 36.3 m and of 15.3 m since pembro cessation (2-31, SD 8.3), only 3% of pts experienced melanoma recurrence. Median recurrence-free survival was not achieved. These 2 pts received radiotherapy, with one partial response achieved. 5 pts died, with 2 deaths unrelated to melanoma (1 lymphoma, 1 chylothorax), 1 related to melanoma progression, and 2 of unknown causes.
Conclusions
In this large real-life cohort, 10% of pts reached CR and discontinued pembro. All but 3% were recurrence-free after a median 15.3 m of treatment, thus validating the discontinuation of anti-PD1 in complete responders.
Clinical trial identification
CCTIRS, #15.640.
Editorial acknowledgement
RIC-Mel network and their team.
Legal entity responsible for the study
MSD France.
Funding
MSD France.
Disclosure
P. Saiag: Honoraria (self), Advisory / Consultancy: MSD. L. Mortier: Honoraria (self), Advisory / Consultancy: MSD. C. Dutriaux: Honoraria (self), Advisory / Consultancy: MSD. L. Benmahammed: Full / Part-time employment: MSD. O. Morsli: Full / Part-time employment: MSD. C. Train: Full / Part-time employment: ClinSearch. A. Spampinato: Full / Part-time employment: MSD. M.T. Leccia: Honoraria (self), Advisory / Consultancy: MSD. N. Meyer: Advisory / Consultancy: MSD. J.J. Grob: Honoraria (self), Advisory / Consultancy: MSD.
Resources from the same session
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract